MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Nevro touts 12-month data for 10 kHz spinal cord stimulation

Nevro touts 12-month data for 10 kHz spinal cord stimulation

By

NevroNevro (NYSE:NVRO) today reported positive 12-month data from the Senza-NSRBP randomized controlled trial of its implantable neurostimulation device for back pain.

Redwood City, California–based Nevro’s data, published in Journal of Neurosurgery: Spine, showed that high-frequency 10 kHz spinal cord stimulation (SCS) therapy results in profound improvement in non-surgical refractory back pain (NSRBP) patients in comparison to conventional medical management (CMM).

Outcomes from 121 patients implanted with 10 kHz SCS, including those who crossed over from the CMM arm to 10 kHz therapy, displayed benefits such as 78.2% of participants reporting pain relief, with the average pain relief registering at 72.1% (70.4% in the crossover arm).

The study demonstrated adverse event report rates similar to what has been reported before, including the Senza-RCT, with only three of 145 permanent SCS devices explanted (all due to wound complications) for an explant rate of 2.1%. There were no explants due to loss of efficacy.

Nevro also reported functional improvement that included 75% of subjects receiving 10 kHz therapy having clinically significant improvement in scores on the Oswestry Disability Index (ODI). In addition, despite no specified opioid weaning protocol, usage in the study declined significantly by 46% on average in subjects receiving treatment at six and 12 months, according to a news release.

“We are thrilled that our 12-month NSRBP trial results clearly demonstrate the durable pain relief that can be achieved with 10 kHz therapy,” Nevro Chairman, CEO and President D. Keith Grossman said in the release. “We look forward to expanding access to high-frequency SCS therapy by providing the needed evidence of clinical benefit and reduced health care utilization when 10 kHz Therapy is used to treat refractory back pain in patients who have not had previous spine surgery.

“No other SCS treatment has demonstrated such positive results in treating NSRBP patients, and we look forward to using this data to support increased patient access and improve market awareness and penetration.”

In case you missed it

RSS From Medical Design & Outsourcing

  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]
  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heatwave in Texas took at least six power plants offline Friday, with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no indication… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]